Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 55Precursor Cell Lymphoblastic Leukemia-Lymphoma 42Leukemia 39Myelodysplastic Syndromes 29Congenital Abnormalities 12Lymphoma, Non-Hodgkin 9Leukemia, Myelomonocytic, Acute 8Leukemia, Monocytic, Acute 8Leukemia, Megakaryoblastic, Acute 8Leukemia, Erythroblastic, Acute 8Leukemia, Biphenotypic, Acute 8Recurrence 7Lymphoma 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Hematologic Neoplasms 7Leukemia, Myelomonocytic, Chronic 6Hodgkin Disease 6Leukemia, Lymphocytic, Chronic, B-Cell 5Leukemia, Eosinophilic, Acute 5Leukemia, Basophilic, Acute 5Leukemia, Promyelocytic, Acute 4Leukemia, Myeloid, Accelerated Phase 4Blast Crisis 4Anemia, Refractory, with Excess of Blasts 4Neoplasms 3Multiple Myeloma 3Lymphoma, B-Cell 3Leukemia, Myelomonocytic, Juvenile 3Graft vs Host Disease 3Burkitt Lymphoma 3

Interventions

ruxolitinib 4Imatinib Mesylate 3ponatinib 2nilotinib 2Azacitidine 2spartalizumab 1sonidegib 1simtuzumab 1sabatolimab 1bosutinib 1Zoledronic Acid 1SCIO-469 1Lenalidomide 1Denosumab 1Decitabine 1Clofarabine 1CPI-0610 14-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Bone Marrow Diseases × Clofarabine × Clear all
NCT01629082 2019-12-17

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
4 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Myelodysplastic Syndromes, Neutropenia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡